Cited by 470Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

The DOI matches its Crossref record.

Residual Symptoms in Depressed Patients Who Respond Acutely to Fluoxetine

Nierenberg, Andrew A., Keefe, Bronwyn R., Leslie, Vinita C., Alpert, Jonathan E., Pava, Joel A., Worthington, John J., Rosenbaum, Jerrold F., Fava, Maurizio·1999·The Journal of Clinical Psychiatry

DOI 10.4088/jcp.v60n0403

Open this paper in CoChat — free account

Abstract

BACKGROUND: Antidepressants have unequivocal efficacy as compared with placebo, but many patients have residual symptoms despite a robust response to antidepressant therapy. The purpose of this study is to assess residual symptoms in outpatients who respond acutely to fluoxetine. METHOD: Two hundred and fifteen outpatients with major depressive disorder as assessed with the Structured Clinical Interview for DSM-III-R (SCID-P) were treated openly with fluoxetine 20 mg/day for 8 weeks. One hundred and eight (50.2%) were considered full responders (final 17-item Hamilton Rating Scale for Depression [HAM-D] score < or =7). Percentages of full responders who continued to have subthreshold or full major depressive disorder symptoms were calculated. The relationship between residual symptoms and Axis I and Axis II (assessed with SCID-II for personality disorders) comorbidity was assessed. RESULTS: Of the 108 responders, 19 (17.6%) had no subthreshold or threshold SCID-P major depressive disorder symptoms, while 28 (25.9%) had 1 symptom, and 61 (56.5%) had 2 or more symptoms. No statistically significant relationships were found between number of residual symptoms and selected Axis I comorbid conditions or total number of Axis II disorders. CONCLUSION: Less than 20% of full responders to fluoxetine by HAM-D criteria were free of all SCID-P subthreshold and threshold major depressive disorder symptoms after 8 weeks of treatment. While depressed patients benefit from antidepressants, most continue to have some symptoms of depression. The high prevalence of residual symptoms among antidepressant responders suggests the need for further study including whether residual symptoms abate with longer treatment or increased dose of fluoxetine. Other strategies, such as cognitive behavioral therapy, may be needed to address residual symptoms.

Integrity signals

Registry

Crossref · 10.4088/jcp.v60n0403

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 301–400 of 465

The relationship between insomnia and major depressive disorder: a chicken and egg situation?
Güleç, M., Özcan, H., Oral, E., Selvı, Y., & Aydın, A. (2012) · Journal of Mood Disorders · doi:10.5455/jmood.20120208025502 · Cited by 12
“Nierenberg and his colleagues assessed the prevalence of residual symptoms in a sample of 215 patients taking open-label fluoxetine 20 mg for 8 weeks; of the original sample, 108 achieved remission (HAMD-17 score ≤7), yet 44% continued to complain of problems with sleep (16).”
Background
Depression, Fatigue, and Pre-Sleep Arousal: A Mediation Model
Karlson, C., Stevens, N. R., Olson, C. A., & Hamilton, N. A. (2010) · Journal of College Student Psychotherapy · doi:10.1080/87568225.2010.509259 · Cited by 12
“In addition, fatigue is one of the most common residual symptoms of depression for patients treated with psychotropic medications (Nierenberg et al., 1999; Worthington et al., 1995) and psychotherapy (Barkham et al., 1996; Kopta, Howard, Lowry, & Beutler, 1994).”
Background
The Illness Density Index (IDI): A longitudinal measure of treatment efficacy
Kelley, M. E., Franco, A. R., Mayberg, H. S., & Holtzheimer, P. E. (2012) · Clinical Trials · doi:10.1177/1740774512450099 · Cited by 12
Cognitive Behavioral Therapy for Insomnia: Is it Effective in Treating Symptoms of Comorbid Psychiatric and Medical Disorders? A Review
Suh, S. A. (2015) · Sleep Medicine Research · doi:10.17241/smr.2015.6.1.10 · Cited by 12
Modelling of serotonin reuptake inhibitory and histamine H 3 antagonistic activity of piperazine and diazepane amides: QSAR rationales for co-optimization of the activity profiles
Sharma, B. K., Singh, P., Shekhawat, M., et al. (2011) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2011.569895 · Cited by 11
“Although these inhibitors are effective in many cases, they have a slow onset of action and little effect on cognitive impairment and fatigue [2,3].”
Background
Factors affecting early attrition and later treatment course of antidepressant treatment of depression in naturalistic settings: An 18-month nationwide population-based study
Pan, Y., Liu, S.-K., & Yeh, L. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.005 · Cited by 11
Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren
Møller, H. J. (2005) · Springer eBooks · doi:10.1007/3-540-28049-9_2 · Cited by 11
Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors
Konuk, N., Atasoy, N., Atik, L., & Akay, Ö. (2006) · Advances in Therapy · doi:10.1007/bf02850053 · Cited by 11
A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response
Goméni, R., Goyal, N., Bressolle, F., & D, M. F. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.105 · Cited by 11
Self-citation
Modafinil Augmentation of Phenelzine for Residual Fatigue in Dysthymia
Ashton, A. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1716-a · Cited by 11
Management of major depressive disorder following failure of first antidepressant treatment
Shelton, R. C. (2006) · Primary psychiatry · Cited by 11
Standardized clinical outcome rating scale for depression for use in clinical practice
Zimmerman, M. A., Posternak, M. A., Chelminski, I., & Friedman, M. (2005) · Depression and Anxiety · doi:10.1002/da.20046 · Cited by 10
“It is possible for patients to be simultaneously classified as in remission by scoring at or below the HRSD remission threshold of 7, and also fully meet DSMIV criteria for major depression [Nierenberg et al., 1999].”
Background
Sleep quality predicts future mood symptoms in adolescents with bipolar disorder
Stepan, M. E., Franzen, P. L., Teresi, G. I., Rode, N., & Goldstein, T. R. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.069 · Cited by 11
“However, there may be a limit to how much sleep quality will improve without explicit sleep intervention (Nierenberg et al., 1999).”
Metabolic factors modulate effort-based decision-making in major depressive disorder
Gill, H., Badulescu, S., Vincenzo, J. D. D., Tabassum, A., Mckenzie, A., Shah, H., Amin, M., Llach, C.-D., Rosenblat, J. D., McIntyre, R. S., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.090 · Cited by 12
The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine
Sarfati, D., Evans, V. C., Tam, E. M., Woo, C., Iverson, G. L., Yatham, L. N., & Lam, R. W. M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000192 · Cited by 10
“Fatigue may also persist as a residual symptom even when other depressive symptoms have improved (Fava et al., 2014); for example, in one study, 39% of patients in symptom remission continued to experience residual fatigue (Nierenberg et al., 1999).”
Background
Comorbid Insomnia: Reciprocal Relationships and Medication Management
Glidewell, R. N., Moorcroft, W. H., & Lee-Chiong, T. L. (2010) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2010.08.012 · Cited by 10
Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2)
Matza, L. S., Murray, L. T., Phillips, G. A., Konechnik, T. J., Dennehy, E. B., Bush, E. N., & Revicki, D. A. (2015) · Patient · doi:10.1007/s40271-014-0107-7 · Cited by 10
“Fatigue is one of the most common symptoms of MDD [24–27], and it has been shown to be a residual symptom that may persist in approximately 20–38 % of patients who have remitted [14, 28, 29].”
Background
Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
Freeman, M. P., D, M. F. M., Gommoll, C., Chen, C., Greenberg, W. M., & Ruth, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000104 · Cited by 12
“Several important studies have brought attention to the problem of residual fatigue (Nierenberg et al., 1999; Greco et al., 2004; Fava et al., 2006; Ferguson et al., 2014), but they have generally been limited to SSRI treatments and have used openlabel or naturalistic study designs.”
BackgroundSelf-citation
Residual symptoms in depression.
Iglesias, C., & Alonso, M. (2009) · PubMed · Cited by 10
Neurobiological predictors for clinical trajectories in fully remitted depressed patients
Blank, T. S., Meyer, B. M., Rabl, U., Schögl, P., Wieser, M., & Pezawas, L. (2020) · Depression and Anxiety · doi:10.1002/da.23108 · Cited by 8
“The rate of MDD patients who achieve full remission but continue to have residual symptoms is up to 80% (Nierenberg et al., 1999) often requiring long‐ term maintenance treatment to forestall recurrent episodes (National Collaborating Centre for Mental Health (UK), 2010).”
BackgroundInfluential
Long-Term Management of Depression
Shelton, R. C. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.05 · Cited by 10
“Reprinted with permission from Nierenberg et al.(6)”
Residual Anxiety Symptoms in Depressed Primary Care Patients
McIntyre, R. S., Konarski, J. Z., Soczynska, J. K., & Kennedy, S. H. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000265772.26627.99 · Cited by 10
Food for thought: understanding the value, variety and usage of management algorithms for major depressive disorder
Katzman, M. A., Anand, L., Furtado, M., & Chokka, P. R. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70002-2 · Cited by 9
“Current definitions of remission (HAM-D ≤ 7 or MADRS ≤ 10) do not necessarily imply a symptom-free state (Nierenberg et al., 1999).”
Background
Recognizing and Effectively Treating Depression
Lecrubier, Y. (2008) · CNS Spectrums · doi:10.1017/s109285290002825x · Cited by 9
Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis
Lam, R. W. M., Wajsbrot, D., Meier, E., Pappadopulos, E. A., Mackell, J. A., & Boucher, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117719261 · Cited by 9
“Even after successful treatment of depressed mood, some symptoms of MDD persist; among the most common residual symptoms in patients remitted from MDD are fatigue and lack of energy (Conradi et al., 2011; Fava et al., 2006, 2014; Nierenberg et al., 1999; Vaccarino et al., 2008).”
Background
Sleep symptoms and long-term outcome in adolescents with major depressive disorder: a naturalistic follow-up study
The Adolescent Depression Study Group, Urrila, A. S., Kiviruusu, O. H., Haravuori, H., Karlsson, L., Viertiö, S., Suvisaari, J., & MARTTUNEN, M. J. (2019) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-019-01436-z · Cited by 9
Treatment-Refractory Depression
Trivedi, M. H., Bettinger, T. L., & Kleiber, B. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18500-7_16 · Cited by 9
Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors
Letavic, M. A., Stocking, E. M., Barbier, A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.061 · Cited by 9
Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders
Застрожин, М. С., Skryabin, V. Y., Sorokin, A., Buzik, O. Z., Александровна, Б. И., Гришина, Е. А., Ryzhikova, K., Шипицын, В. В., Bryun, E. A., & Sychev, D. A. (2020) · Drug metabolism and drug interactions · doi:10.1515/dmpt-2019-0033 · Cited by 9
Clinical Significance and Remission in Treating Major Depressive Disorder: Parallels Between Related Outcome Constructs
McGlinchey, J. B., Zimmerman, M. A., & Atkins, D. C. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220701885815 · Cited by 8
Dual serotonin transporter inhibitor/histamine H3 antagonists: Development of rigidified H3 pharmacophores
Keith, J. M., Barbier, A., Wilson, S. J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.017 · Cited by 8
Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder
Lecrubier, Y., Dolberg, O. T., Andersen, H. F., & Weiller, E. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0771-x · Cited by 8
“[30] for the residual symptomatology in responders with an initial diagnosis of depression.”
Background
Mood Disorders
Peterson, M. J., & Benca, R. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6645-3.00130-4 · Cited by 12
Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study
Shrashimirova, M., Tyanev, I., Cubała, W. J., Wichniak, A., Vodickova-Borzova, C., Ruggieri, A., Bonelli, A., Lipone, P., Comandini, A., & Cattaneo, A. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s399948 · Cited by 7
“To our knowledge, this is the first observational study to assess the long-term clinical response of TzOAD in patients with MDD. Data were collected from a large population (n=200) across 26 sites in 3 European countries (Bulgaria, Czech Republic, and Poland).”
BackgroundInfluential
Aneurysmal subarachnoid haemorrhage: effect of CRHR1 genotype on fatigue and depression
Vetkas, A., Prans, E., Kõks, S., Rätsep, T., & Asser, T. (2020) · BMC Neurology · doi:10.1186/s12883-020-01727-y · Cited by 7
“Fatigue can persist after successful treatment of major depression and it requires distinct interventions [30].”
Background
Sommeil, insomnie et psychopathologie.
Morin, C. M., Bélanger, L., & Fortier-Brochu, É. (2006) · Canadian Psychology/Psychologie canadienne · doi:10.1037/cp2006016 · Cited by 10
A two-phase, prescriptive comparative effectiveness study to optimize the treatment of co-occurring insomnia and depression with digital interventions
Pigeon, W. R., Bishop, T. M., Bossarte, R. M., Schueller, S. M., & Kessler, R. C. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107306 · Cited by 6
Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds.
Girone, N., Benatti, B., Molteni, L., Cassina, N., Giacovelli, L., Arici, C., & Dell’Osso, B. M. (2023) · PubMed Central · doi:10.36131/cnfioritieditore20230303 · Cited by 6
“Furthermore, though the existence of several antidepressant medications, the research found that the efficacy is still partial, even when patients report levels of remission, with subclinical residual symptoms that may hamper the individuals’ functioning and their quality of life (Nierenberg et al., 1999; Fava, 1999;…”
Background
Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial
Bould, H., Wiles, N., Potokar, J. P., Cowen, P. J., Nutt, D., Peters, T. J., & Lewis, G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431753 · Cited by 6
Trajectory of criterion symptoms of major depression under newly started antidepressant treatment: sleep disturbances and anergia linger on while suicidal ideas and psychomotor symptoms disappear early
Tajika, A., Furukawa, T. A., Inagaki, M., Kato, T., Mantani, A., Kurata, K., Ogawa, Y., Takeshima, N., Hayasaka, Y., Noma, H., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13115 · Cited by 7
“After an open trial of 8 weeks of fluoxetine administration, sleep problems and fatigue were the most frequent residual symptoms and severe symptoms while psychomotor symptoms and suicidal ideas the least so according to the Structured Clinical Interview for DSM-III-R (12).”
Background
Digital cognitive–behavioural therapy for insomnia compared with digital patient education about insomnia in individuals referred to secondary mental health services in Norway: protocol for a multicentre randomised controlled trial
Kallestad, H., Saksvik, S. B., Vedaa, Ø., Langsrud, K., Morken, G., Lydersen, S., Simpson, M. R., Dørheim, S. K., Holmøy, B., Selvik, S. G., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050661 · Cited by 7
Treatment-resistant residual insomnia in patients with recurrent major depressive episodes
IWAKI, S., Satoh, K., MATSUMOTO, Y., Echizenya, M., KATOH, T., Kusanagi, H., Kitamura, S., Shimizu, T., & Mishima, K. (2012) · Sleep and Biological Rhythms · doi:10.1111/j.1479-8425.2012.00564.x · Cited by 6
Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study
Edinger, J. D., Manber, R., Buysse, D. J., Krystal, A. D., Thase, M. E., Gehrman, P. R., Fairholme, C. P., Luther, J. F., & Wisniewski, S. R. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6448 · Cited by 6
“, continuous positive airway pressure) for their sleep apnea; however, those with AHI ≥ 5 and < 10 were allowed to enroll since our clinical experience has suggested that such cases with insomnia benefit by CBT-I, (6) other primary sleep disorders including restless legs syndrome experienced more than once a week, per…”
Unipolar Major Depression
Minkel, J. D., Krystal, A. D., & Benca, R. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24288-2.00137-9 · Cited by 10
Collaborative depression care, screening, diagnosis and specificity of depression treatments in the primary care setting
Alexander, J. L., Richardson, G., Grypma, L., & Hunkeler, E. M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11s.s59 · Cited by 6
Differentiating Residual symptoms of Depression from Adverse Events among Patients Initiating Treatment with An Antidepressant
Freeman, M. P., Fisher, L. B., Clain, A. J., Rabbitt, R., Pooley, J. P., Baer, L., & D, M. F. M. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900107 · Cited by 6
Self-citation
Residual hypersomnia in unipolar and bipolar depression: A systematic review
Kwaśna, J., Kwaśny, A., Wilkowska, A., Bychowski, M., & Cubała, W. J. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2429429 · Cited by 6
“Notably, hypersomnia persists as a prevalent residual symptom in MDD (Nierenberg et al. 1999; Fava et al. 2002; Fava 2003).”
Impact of trazodone once‐a‐day on quality of life and functional recovery in adults with major depressive disorder: A prospective, observational study
Tellone, V., Markovič, O., Strashimirova, M., Sani, G., Lenderking, W. R., Margolis, M. K., Fallone, R., Quarchioni, E., Cattaneo, A., & Comandini, A. (2024) · Brain and Behavior · doi:10.1002/brb3.3580 · Cited by 5
“Delayed onset of action is a limitation of some antidepressant treatments (e.g., SSRIs and SNRIs), which may lead to non-compliance, poor outcomes, and treatment failures (Nierenberg et al., 1999; Trivedi et al., 2006).”
Background
Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan
Wu, Y.-S., Chen, Y., & Lu, R. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00828.x · Cited by 6
Unipolare Depression – Pharmakotherapie und Psychotherapie (ICD-10 F3)
Schmauß, M., Schramm, E., & Berger, T. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50011-3 · Cited by 5
Psychological and Behavioral Treatments for Insomnia II
Edinger, J. D., Means, M. K., Carney, C. E., & Manber, R. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6645-3.00080-3 · Cited by 5
Medication options in the treatment of treatment-resistant depression
PRIDMORE, S. A., & Turnier‐Shea, Y. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01335.x · Cited by 5
Psychiatry and Sleep
Berry, R. B. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0326-9.00029-4 · Cited by 6
Evaluation and Management of Insomnia in the Psychiatric Setting
Doghramji, K., Grewal, R. G., & Markov, D. (2009) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.7.4.foc441 · Cited by 5
Relationship of Variability in Residual Symptoms With Recurrence of Major Depressive Disorder During Maintenance Treatment
Karp, J. F., Buysse, D. J., Houck, P. R., Cherry, C. R., Kupfer, D. J., & Frank, E. (2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.161 · Cited by 4
Insomnia and Depression: A Reciprocal Relationship
Herrick, D. D., & Sateia, M. J. (2016) · Psychiatric Annals · doi:10.3928/00485713-20160121-01 · Cited by 4
Predictors of Clinical Recovery in Bipolar Disorders
Fico, G., Anmella, G., Murru, A., & Vieta, E. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_10 · Cited by 5
Regarding “combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind randomized study”: Optimizing initial interventions
Farber, G. A., & Goldberg, J. F. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.013 · Cited by 4
Psychiatric Diagnoses of Patients Visiting a Sleep Disorder Clinic Due to Dyssomnias
Hsu, S., Liu, C.-Y., & Chen, N. (2006) · Psychological Reports · doi:10.2466/pr0.98.3.789-797 · Cited by 4
Tratamiento farmacológico de las depresiones resistentes
Martínez, L. G. (2002) · Revista de la Asociación Española de Neuropsiquiatría · doi:10.4321/s0211-57352002000200004 · Cited by 4
“Aunque podríamos suponer que la remisión de un episodio depresivo fuera equivalente a la ausencia de síntomas, en investigación clínica se considera remisión el hecho de alcanzar un punto de corte de la escala HAM-D de entre 7 y 10 puntos, a pesar de que incluso una puntuación menor de 7 refleja la existencia de sínto…”
Background
Clinical effectiveness, construct and assessment
Patten, S. B., Grigoriadis, S., & Beaulieu, S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.045 · Cited by 4
“In one study of depressed patients treated with fluoxetine, 80% of patients who achieved remission reported having at least one residual symptom (Nierenberg et al., 1999).”
BackgroundInfluential
Nature and Treatment of Insomnia
Morin, C. M., Savard, J., & Ouellet, M. (2012) · Wiley eBooks · doi:10.1002/9781118133880.hop209014 · Cited by 4
Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression
Landrum, R. E., Raines, A. M., Harvey, P. D., Banov, M. D., Saulnier, K. G., & Moore, M. B. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002060 · Cited by 4
Differentiating Depressive Symptoms From Side Effects in Individuals With Major Depressive Disorder With Postpartum Onset
Pulido, C. M., Walson, I. S., Yang, A., Stika, C. S., Sit, D. K. Y., & Wisner, K. L. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001928 · Cited by 3
" A Motor Imagery Training for Improving Action Cognition Results in the Reduction of Residual Symptoms after Major Depressive Disorder: A Single-Case Study"
Tiba, A., & Manea, L. (2022) · Journal of Evidence-Based Psychotherapies · doi:10.24193/jebp.2022.1.8 · Cited by 2
Combination of low doses of mirtazapine plus venlafaxine produces antidepressant-like effects in rats, without affecting male or female sexual behavior
Silva, A. Á., Rodríguez–Manzo, G., Reyes, R., & Fernández‐Guasti, A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06661-2 · Cited by 3
Direct and Indirect Costs of Sleep Disturbances and Residual Symptoms in Patients Treated for Depression
Gupta, S., Goren, A., Kim, E., Gabriel, S., & Dupclay, L. (2012) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e31825107da · Cited by 3
The use of psychotropic medications for chronic insomnia in clinical practice
Poluektov, M. G. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112104261 · Cited by 3
Behavioral treatment of insomnia
Means, M. K., & Edinger, J. D. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.1.127 · Cited by 3
Síntomas residuales y remisión en la depresión: una encuesta de opinión entre psiquiatras españoles
García, M. B., Laraña, M. C., & Prieto, J. F. P. (2007) · Psiquiatría Biológica · doi:10.1016/s1134-5934(07)73266-9 · Cited by 3
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · doi:10.3109/9781420084887-5 · Cited by 3
Sleep Dysregulation and Related Regulatory Models
Germain, A., & Thase, M. E. (2008) · Elsevier eBooks · doi:10.1016/b978-0-08-045078-0.00005-8 · Cited by 3
Defining and Differentiating Treatment-Resistant Depression
Treviño, K. (2012) · Cited by 3
Post-stroke Fatigue: Refining the Concept
Giacobbe, P. (2010) · TSpace (University of Toronto) · Cited by 3
Combining and Augmenting: Choosing the Right Therapies for Treatment-resistant Depression
Zajecka, J., & Goldstein, C. (2005) · Psychiatric Annals · doi:10.3928/00485713-20051201-06 · Cited by 3
Dépression en rééducation
Wirotius, J.-M., & Pétrissans, J.-L. (2005) · EMC - Kinésithérapie · doi:10.1016/j.emckns.2005.07.001 · Cited by 3
“On estime le chiffre des « répondeurs » [79] entre 50 et 70 % et celui des patients qui n’ont pas d’effet clinique à 20 %.”
TOWARDS PERSONALIZED TREATMENT OF DEPRESSION
Gerasimchuk, M. Y. (2016) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2016-6-4-8-13 · Cited by 2
Clustering and drivers of symptoms observed at week six after antidepressant treatment in depressed outpatients
Danon, M., Poupon, D., Courtet, P., & Gorwood, P. A. P. M. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1801 · Cited by 1
“However,theremainingsymptomsarenotevenlydistributed,for example,poorconcentration,sleepdisturbancesandlackofenergy/ fatigue,andanxietyweremorefrequentlyobserved[4,24,25].”
DIAGNÓSTICO, EVALUACIÓN Y TRATAMIENTO DE LA DEPRESIÓN CRÓNICA
Moerk, K. C. (2000) · Psicología conductual = behavioral psychology: Revista internacional de psicología clínica y de la salud · Cited by 2
Measuring depressive symptoms in the naturalistic primary-care setting
McIntyre, R. S., Konarski, J. Z., Kennedy, S. H., Dickens, S. E., & Bagby, R. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01448.x · Cited by 2
Pursuing treatments that are not evidence based: How DSM IV clarifies, how it blinds psychiatrists to issues in need of investigation
Sobo, S. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2008.12.022 · Cited by 2
Modafinil/armodafinil in the treatment of excessive daytime sleepiness
Monderer, R. S., & Thorpy, M. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511762697.038 · Cited by 2
The Effect of Sleep Disturbances on Major Depressive Disorder.
Pigeon, W. R. (2009) · PubMed · Cited by 2
Cognitive Behaviour Therapy for Insomnia in Co-morbid Psychiatric Disorders
O'Regan, D. J. (2018) · Springer eBooks · doi:10.1007/978-3-642-54836-9_9 · Cited by 2
Treatment of depression through normalisation of sleep–wake rhythm disorders
III Klinika Psychiatryczna, I. P. I. N., Wichniak, A., Ośrodek Medycyny Snu, Z. N. K., Szmyd, J., & III Klinika Psychiatryczna, I. P. I. N. (2019) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2019.0036 · Cited by 1
“Jako objaw rezydualny, utrzymujący się mimo ustąpienia innych objawów depresji, bezsenność może być obecna na-wet u 44–51% chorych, zarówno w przypadku stosowania farmakoterapii, jak i leczenia depresji terapią poznawczo--behawioralną (Carney et al. , 2007; Nierenberg et al. , 1999).”
Sleep Disorders
Weilburg, J. B., Stakes, J. W., & Roth, T. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50024-x · Cited by 3
Pharmacologic Treatment of Insomnia
Mishima, K. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_137 · Cited by 2
The Evolution of Insomnia in Relation to Comorbidity
Drake, C. L., Schwartz, J. R. L., & Roth, T. G. (2008) · Psychiatric Annals · doi:10.3928/00485713-20080901-02 · Cited by 3
Clinical study results from a randomized controlled trial of cognitive behavioural guided self-help in patients with partially remitted depressive disorder.
Schlögelhofer, M., Willinger, U., Wiesegger, G., Eder, H., Priesch, M., Itzlinger, U., Bailer, U., Schosser, A., Leisch, F., & Aschauer, H. (2014) · Psychology and psychotherapy · doi:10.1111/papt.12008 · Cited by 3
Insomnia Diagnosis and Classification
Buysse, D. J. (2010) · Medical psychiatry · doi:10.3109/9781420080803.011 · Cited by 2
The Treatment of Comorbid Insomnia
McCall, W. V. (2009) · CNS Spectrums · doi:10.1017/s1092852900003965 · Cited by 2
Rezidivierende kurze depressive Störung. Übersicht und eigene klinische Erfahrungen zu einer unterdiagnostizierten Depressionsform
Pezawas, L., Kasper, S. F., & Stamenkovic, M. (2001) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 2
The association between sleep and eating disorders in Canada before and during the first wave of the COVID-19 pandemic
Kenny, S., Robillard, R., Saad, M., Kendzerska, T., Quilty, L. C., Solomonova, E., Lee, E. K., Daros, A. R., Godbout, R., & Pennestri, M. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100860 · Cited by 1
The effect of systematic antidepressant treatments in the early stages on sleep and impulsivity in bipolar euthymic patients: A cross-sectional study
Wang, M., An, X., Han, D., Hou, X., & Yang, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322274 · Cited by 2
“Additionally, Nierenberg et al. reported that sleep issues are prevalent residual symptoms in depressives achieving clinical remission (scores of the Hamilton Depression Rating Scale ≤ 7) [50].”
Six-year trajectories of core depressive symptoms and insomnia symptoms in depressed older adults: a NESDO study
Kerpershoek, M. L., Giltay, E., Kok, A., Kok, R. M., Oudega, M., Voshaar, R. O., Ottenheim, N. R., Veltman, E., & van den Berg, J. F. (2025) · Aging & Mental Health · doi:10.1080/13607863.2025.2496730 · Cited by 1
Photobiomodulation as a Therapeutic Strategy for Major Depressive Disorder: Mechanisms and Prospects
Hu, S., Li, X., Guo, B., Xu, W., Liu, T. C., & Yang, L. (2025) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1177/25785478251371716 · Cited by 1
“87 In addition to impairing the quality of life, remaining symptoms are also capable of resulting in an unfavorable prognosis.”
Anhedonia in patients with major depressive disorder (MDD): State-of-the-art consensus review
Cutler, A. J., Clayton, A. H., Krystal, A. D., Maletic, V., McIntyre, R. S., & Nemeroff, C. B. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117225 · Cited by 3
Sleep, Sadness, and Depression
Manber, R., & Fairholme, C. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417188-6.00011-6 · Cited by 1
Insomnie chez l'adulte
Bélanger, L., & Morin, C. M. (2012) · Elsevier eBooks · doi:10.1016/b978-2-294-71025-4.00013-0 · Cited by 1
Síntomas residuales de la depresión: terapias coadyuvantes
Flores, E. O., Muñiz., S. D. I. C. I. N. D. P. R. D. L. F., Camarena, V. A. T., & González, J. J. (2015) · Salud Mental · doi:10.17711/sm.0185-3325.2015.009 · Cited by 1

Authors: Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M.
Affiliations: Massachusetts General Hospital (US)
Harvard University (US)
ORCID: Nierenberg, Andrew A.
Keefe, Bronwyn R.
Alpert, Jonathan E.
Worthington, John J.
Venue: The Journal of Clinical Psychiatry
Publisher: Physicians Postgraduate Press, Inc
Published: 1999-04-15
Volume: 60
Issue: 4
Pages: 221-225
ISSN: 0160-6689 (ISSN-L)
DOI: 10.4088/jcp.v60n0403
OpenAlex: W2056454671
Cited by: 470
References: 0
Citations by year: 2026: 8 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 11 · 2021: 10 · 2020: 9 · 2019: 19 · 2018: 10 · 2017: 8 · 2016: 16 · 2015: 22 · 2014: 17 · 2013: 19 · 2012: 30
FWCI: 3.48
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (1r01mh048483-01a1)
National Institute of Mental Health (R01 MH48483-01)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords: residual depressive symptoms, fluoxetine, major depressive disorder, antidepressant response, subthreshold depression, comorbidities, personality disorders, outpatients, cognitive behavioral therapy
MeSH terms: Adult, Ambulatory Care, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Middle Aged, Personality Disorders, Psychiatric Status Rating Scales, Comorbidity, Cognitive Behavioral Therapy, Prevalence, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Age of Onset

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Residual Symptoms in Depressed Patients Who Respond Acutely to Fluoxetine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks